Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.76, $0.32 better than the analyst estimate of $0.44. Revenue for the quarter came in at $33.46 million versus the consensus estimate of $27.2 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.